作者投稿
专家审稿
编辑办公
邮件订阅
RSS
-
摘要: 近年来，国际临床医学领域排名Top10的热点前沿中，屡屡出现分子影像及其一体化精准诊疗，如靶向前列腺特异性膜抗原的前列腺癌精准诊断与治疗。分子影像指导下的一体化精准诊疗是一个飞速发展的领域：针对任何疾病的特征靶点，都有可能找到一种或多种分子探针，通过分子影像观察其在体内的表达及动态变化，用于疾病精准诊断，并一体化指导针对同一靶点的放射性核素治疗、靶向药物治疗和术中光成像精准手术等，因此极具临床应用前景，值得广大医学工作者密切关注。Abstract: In recent years, molecular imaging and precise theranostics have appeared frequently in the Top 10 international hot frontiers in the field of clinical medicine, including accurate diagnosis and therapy of prostate cancer targeting prostate specific membrane antigen (PSMA). Molecular imaging-guided theranostics is a rapidly developing field, which is feasible to find one or more molecular probes for any disease-specific target to observe the in vivo expression and dynamic changes through molecular imaging.The molecular imaging can be applied to accurate diagnosis of diseases, guiding precise therapeutic radionuclide therapy, targeted drugs, and optical imaging-guided surgery. Therefore, it has a great prospect of clinical application and deserves a close attention by the majority of medical researchers and professionals.
-
Key words:
- molecular imaging /
- precise medicine /
- theranostics
作者贡献：王国昌负责查阅文献、撰写论文；朱朝晖负责论文构思及终稿审核、修订。利益冲突：所有作者均声明不存在利益冲突 -
表 1 2017—2021年国际临床医学领域热点前沿Top10中与分子影像及其一体化精准诊疗相关的研究
时间(年) 排名 研究内容 2017 1 放射性核素标记PSMA PET显像在前列腺癌诊疗中的应用 2018 2 阿尔茨海默病18F标记Tau靶向PET成像 5 神经内分泌肿瘤相关研究 8 放射性核素标记PSMA靶向治疗去势抵抗性前列腺癌 2019 5 基于PET的Tau蛋白成像技术用于阿尔茨海默病等神经退行性疾病的研究 2020 9 阿尔茨海默病Tau PET显像 2021 10 PET/CT用于肿瘤免疫治疗评价 PSMA：前列腺特异性膜抗原；PET：正电子发射断层显像 
下载: 导出CSV
-
[1] Weissleder R, Tung CH, Mahmood U, et al. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes[J]. Natbiotechnol, 1999, 17: 375-378. [2] Zerhouni E. Medicine. The NIH roadmap[J]. Science, 2003, 302: 63-72. doi: 10.1126/science.1091867 [3] Gimi B, Pathak AP, Ackerstaff E, et al. Molecular imaging of cancer: applications of magnetic resonance methods[J]. Proc IEEE Inst Electr Electron Eng, 2005, 93: 784-799. doi: 10.1109/JPROC.2005.844266 [4] Lu ZR, Minko T. Molecular imaging for precision medicine[J]. Adv Drug Deliv Rev, 2017, 113: 1-2. doi: 10.1016/j.addr.2017.08.002 [5] Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of 177Lu-DOTATATE for Midgut Neuroendocrine Tumors[J]. N Engl J Med, 2017, 376: 125-135. doi: 10.1056/NEJMoa1607427 [6] Hofman MS, Violet J, Hicks RJ, et al. 177Lu-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study[J]. Lancet Oncol, 2018, 19: 825-833. doi: 10.1016/S1470-2045(18)30198-0 [7] Liu Q, Zang J, Sui H, et al. Peptide receptor radionuclide therapy of late-stage neuroendocrine tumor patients with multiple cycles of177Lu-DOTA-EB-TATE[J]. J Nucl Med, 2021, 62: 386-392. doi: 10.2967/jnumed.120.248658 [8] Zang J, Fan X, Wang H, et al. First-in-human study of177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer[J]. Eur J Nucl Med Mol Imaging, 2019, 46: 148-158. doi: 10.1007/s00259-018-4096-y [9] Osl T, Schmidt A, Schwaiger M, et al. A new class of Pentixa For- and Pentixa Ther-based theranostic agents with enhanced CXCR4-targeting efficiency[J]. Theranostics, 2020, 10: 8264-8280. doi: 10.7150/thno.45537 [10] Ballal S, Yadav MP, Kramer V, et al. A theranostic approach of[68Ga]Ga-DOTA. SA. FAPi PET/CT-guided[177Lu]Lu-DOTA. SA. FAPi radionuclide therapy in an end-stage breast cancer patient: new frontier in targeted radionuclide therapy[J]. Eur J Nucl Med Mol Imaging, 2021, 48: 942-944. doi: 10.1007/s00259-020-04990-w [11] Jauw YW, Zijlstra JM, de Jong D, et al. Performance of 89Zr-labeled-Rituximab-PET as an imaging biomarker to assess CD20 targeting: a pilot study in patients with relapsed/refractory diffuse large B cell lymphoma[J]. PLoS One, 2017, 12: e0169828. doi: 10.1371/journal.pone.0169828 [12] Biabani Ardakani J, Akhlaghi M, Nikkholgh B, et al. Targeting and imaging of HER2 overexpression tumor with a new peptide-based 68Ga-PET radiotracer[J]. Bioorg Chem, 2021, 106: 104474. doi: 10.1016/j.bioorg.2020.104474 [13] Sun X, Xiao Z, Chen G, et al. A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management[J]. Sci Transl Med, 2018, 10: eaan8840. doi: 10.1126/scitranslmed.aan8840 [14] Read ED, Eu P, Little PJ, et al. The status of radioimmunotherapy in CD20+ non-Hodgkin's lymphoma[J]. Target Oncol, 2015, 10: 15-26. doi: 10.1007/s11523-014-0324-y [15] Niemeijer AN, Leung D, Huisman MC, et al. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer[J]. Nat Commun, 2018, 9: 4664. doi: 10.1038/s41467-018-07131-y [16] Xing Y, Chand G, Liu C, et al. Early phase I study of a 99mTc-labeled anti-programmed death ligand-1 (PD-L1) single-domain antibody in SPECT/CT assessment of PD-L1 expression in non-small cell lung cancer[J]. J Nucl Med, 2019, 60: 1213-1220. doi: 10.2967/jnumed.118.224170 [17] Hernot S, van Manen L, Debie P, et al. Latest develop-ments in molecular tracers for fluorescence image-guided cancer surgery[J]. Lancet Oncol, 2019, 20: e354-e367. [18] He K, Chi C, Li D, et al. Resection and survival data from a clinical trial of glioblastoma multiforme-specific IRDye800-BBN fluorescence-guided surgery[J]. Bioeng Transl Med, 2020, 6: e10182. -
点击查看大图
表(1)
计量
- 文章访问数: 1136
- HTML全文浏览量: 109
- PDF下载量: 519
- 被引次数: 0
